OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed colorectal cancer
• * Radiologic evidence of advanced disease
• At least 1 measurable lesion at least 20 mm OR at least 10 mm by spiral CT scan
• * Indicator lesions in a previously irradiated field are allowed provided the irradiated lesion has clearly progressed OR a new lesion has developed in the irradiated field
• Failed 1, and only 1, line of prior chemotherapy for advanced/metastatic disease
• * Disease progression during chemotherapy OR within 6 months after completion of treatment
• No symptomatic brain metastases meeting any of the following criteria:
• * Unstable
• * Inadequately controlled with fixed-dose oral steroids
• * Potentially life-threatening
• * Required radiotherapy with the past 28 days
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Neutrophil count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• Hepatic
• AST and ALT \< 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
• Bilirubin \< 1.5 times ULN
• No hepatitis
• No cirrhosis
• Renal
• Creatinine \< 1.5 times ULN
• Other
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after study participation
• HIV negative
• No preexisting neuropathy ≥ grade 2
• No active or uncontrolled infection
• No other serious illness or medical condition
• No chronic alcohol abuse
• No known hypersensitivity to systemic liposomal formulations or compounds chemically related to OSI-7904L or oxaliplatin
• No prior psychiatric or neurologic condition that would preclude study compliance or giving informed consent
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 21 days since prior immunotherapy
• At least 21 days since prior monoclonal antibody therapy
• Chemotherapy
• See Disease Characteristics
• At least 21 days since prior chemotherapy and recovered\*
• No prior oxaliplatin NOTE: \*Alopecia allowed
• Endocrine therapy
• See Disease Characteristics
• At least 21 days since prior hormonal therapy
• Radiotherapy
• See Disease Characteristics
• At least 21 days since prior radiotherapy and recovered
• No prior radiotherapy to more than 25% of bone marrow reserve
• Surgery
• Recovered from prior surgery
• Other
• At least 21 days since prior tyrosine kinase inhibitor therapy
• More than 21 days since prior investigational agents
• No other concurrent anticancer therapy
• No other concurrent investigational agents